Skip to main content

Bioequivalence in Healthy Subjects

3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Wockhardt
WockhardtNJ - Parsippany
3 programs
3
Insulin LisproPhase 11 trial
Insulin LisproPhase 11 trial
Insulin lisproPhase 11 trial
Active Trials
NCT01400789Withdrawn0
NCT01400802Withdrawn0Est. Jun 2012
NCT01399255Withdrawn0Est. Jun 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
WockhardtInsulin lispro
WockhardtInsulin Lispro

Clinical Trials (3)

NCT01400789WockhardtInsulin Lispro

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Listro Mix 50/50® and Humalog Mix50/50® in Healthy Subjects

0
Phase 1Withdrawn
NCT01399255WockhardtInsulin lispro

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listro™) With Humalog® in Healthy Subjects

Start: Nov 2011Est. completion: Jun 20120
Phase 1Withdrawn
NCT01400802WockhardtInsulin Lispro

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects

Start: Nov 2011Est. completion: Jun 20120
Phase 1Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.